Lian-Wang Guo

Credentials: MS, PhD

Position title: Assistant Professor


Phone: (608) 262-6269

5151 WIMR
1111 Highland Ave
Madison, WI 53705-2275

Guo Lab

Focus Groups


Signal Transduction


PhD, Plant Physiology, Chinese Academy of Sciences

Research Summary

Mechanisms of restenosis, proliferation and inflammation, retinal neurodegeneration and regeneration, neural progenitor/stem cells.

Research Detail

Treatments for cardiovascular disease, including angioplasty and bypass, frequently fail in large part because of the transition of normal vascular smooth muscle cells to a disease state. We have recently identified a molecular switch, that, when pharmacologically turned off, halts this disease-prone cellular transition. We are conducting in-depth research on this exciting finding, which may someday lead to improved methods for treating recurrent vascular disease.

We are focusing on the bromo and extraterminal (BET) family of proteins, termed epigenetic “readers”. In response to pathogenic stimuli, BET proteins couple with cell type- or cell state-specific transcription factors to activate the expression of a select set of genes which in concert drive cellular transition to a disease state. We are working to differentiate the functions of the various BET proteins and bromo-domains in smooth muscle cell pathogenic transition, and to identify the key transcription factors that are governed by BET proteins. To this end, we are making use of the CRISPR/Cas9 technology for knockout and mutagenesis, and ChIPseq and RNAseq for genome wide analyses.

In parallel, Dr. Guo’s laboratory is exploiting the potential of an endogenous neuroprotective pathway, the Sigma-1 receptor chaperone, in retinal neurons against cell death. We wish our research will produce critical knowledge of effective remedies for blinding retinal diseases, or in a broader sense, neurodegenerative diseases.

For translation, Dr. Guo’s lab is collaborating with bioengineering experts Dr. William Murphy and Dr. Sarah Gong and vascular surgeon Dr. Craig Kent to develop targeted drug delivery platforms.

PubMed Search For Lian-Wang Guo